Oxford COVID-19 vaccine trials produce robust immune response in elderly - FT
Monday, 26 October 2020 (Reuters) - Early results from tests for a coronavirus vaccine being developed by the University of Oxford, in collaboration with AstraZeneca Plc, show it produces a robust immune response in elderly people, the group at highest risk,...
The Government could face some “tough choices” if the vaccine produced byAstraZeneca and Oxford University is found to be less effective than others, aformer Department of Health director of immunisation has said. Professor DavidSalisbury said ministers would need to think “very carefully” about theirhandling of the vaccine if its efficacy was lower than for other jabs such asthose from Pfizer/BioNTech and Moderna. The AstraZeneca/Oxford vaccine iscurrently being assessed by the Medicines and Healthcare products RegulatoryAgency (MHRA) for use in the UK.Data from two arms of its phase-three trial,announced last week, gave a combined efficacy of 70%.
Credit: PA - Press Association STUDIO Duration: 00:59Published
AstraZeneca and the University of Oxford are facing criticism over their COVID-19 vaccine trial results. According to Business Insider the criticism comes after AstraZeneca admitted to a mistake in the vaccine dosage. During the vaccine trial, some patients got two full doses of the vaccine. Others had a half-dose in their first shot, followed by a full dose. On Wednesday, an AstraZeneca executive described the "mistake" as "serendipity.
A manufacturing error is raising concerns about a promising COVID-19 vaccine being developed. The vaccine was developed by pharmaceutical company AstraZeneca and the University of Oxford. Less than a week after we learned about it, the developers have admitted to a manufacturing error. The error resulted from two different doses during the recently concluded phase III trial. AstraZeneca and the University of Oxford described the vaccine as being 70% effective.
COVID-19 vaccine will be distributed initially in India, informed Chief executive officer (CEO) of Serum Institute of India, Adar Poonawalla on November 28. He said, "Vaccine will be distributed initially in India, then we will look at the COVAX countries which are mainly in Africa. The UK and European markets are being taken care of by AstraZeneca and Oxford. Our priority is India and COVAX countries." Earlier in the day, Prime Minister Narendra Modi visited Serum Institute of India in Pune, Maharashtra to and reviewed COVID-19 vaccine development.
Even as Oxford and Astra Zeneca said that their Covid-19 vaccine had a 90% efficacy, their claims it turned out were based on an accident. Oxford Astrazeneca said that when volunteers were administered..
By Hannah Clapham*
With COVID-19 cases still rising globally, the race is on for a vaccine. Pressures are mounting to get one available for use as soon as... Eurasia Review Also reported by •Mid-Day •Newsy •SeattlePI.com